Genetic Testing and Clinical Management Practices for Variants in Non-<i>BRCA1</i>/<i>2</i> Breast (and Breast/Ovarian) Cancer Susceptibility Genes: An International Survey by the Evidence-Based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Clinical Working Group
Sarah M. Nielsen(Myriad (Germany)), Jana Soukupová(Myriad (Germany)), Maria A. Caligo(Azienda Ospedaliera Universitaria Pisana), Claude Houdayer(Inserm), Florentia Fostira(National Centre of Scientific Research "Demokritos"), Nicholas Pachter(The University of Western Australia), Mariarosaria Calvello(European Institute of Oncology), Rosalind A. Eeles(Royal Marsden NHS Foundation Trust), Fergus J. Couch(Mayo Clinic), Inge Søkilde Pedersen(Aalborg University Hospital), Nadia Naldi(University of Parma), Maria Cristina Sini(Azienda Ospedaliero Universitaria di Sassari), Thomas van Overeem Hansen(University of Copenhagen), April Morrow(UNSW Sydney), Kathleen Claes(Statistics Belgium), Arjen R. Mensenkamp(Radboud University Nijmegen), Michela Biancolella(University of Rome Tor Vergata), Anna Efremidis(Myriad (Germany)), Siranoush Manoukian(Fondazione IRCCS Istituto Nazionale dei Tumori), Rien Blok(Myriad (Germany)), Henriette Roed Nielsen(Myriad (Germany)), Luigi Mori(University of Brescia), Maria Rossing(Rigshospitalet), Petra Kleiblová(Charles University), Mark E. Robson(Memorial Sloan Kettering Cancer Center), Fahd Al‐Mulla(Dasman Diabetes Institute), Miguel de la Hoya, Andreas Hadjisavvas(Cyprus Institute of Neurology and Genetics), Maria A. Loizidou(Cyprus Institute of Neurology and Genetics), Olufunmilayo I. Olopade(University of Chicago), Laura Cortesi(Azienda Ospedaliero-Universitaria di Modena), Susan M. Domchek(University City Science Center), Sophie Krieger(Inserm), Edenir Inêz Palmero(DASA (Brazil)), Maria Piane(CTO Andrea Alesini), Ángela R. Solano(Consejo Nacional de Investigaciones Científicas y Técnicas), Iris L. Romero(University of Chicago), Álvaro N.A. Monteiro(Moffitt Cancer Center), Conxi Lázaro(Institut d'Investigació Biomédica de Bellvitge), Akira Hirasawa(Okayama University), Judith Balmañà(Vall d'Hebron Hospital Universitari), Simona De Toffol(Myriad (Germany)), Tai-Hua Chan(Myriad (Germany)), David E. Goldgar(Myriad (Germany)), Gabriele Lorenzo Capone(University of Modena and Reggio Emilia), Orland Dı́ez(Vall d'Hebron Hospital Universitari), Setareh Moghadasi(Myriad (Germany)), Marianna Puzzo(Myriad (Germany))
Cited by 28
Related Papers
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline <i>BRCA1/2</i> Mutation
|Journal of Clinical Oncology|2014|1.7k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making
|Annals of Oncology|2012|1.5k
Sensitive and specific multi-cancer detection and localization using methylation signatures in cell-free DNA
|Annals of Oncology|2020|1.5k